Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Mai 2015 16:01 ET | Quelle: Otonomy, Inc.

Otonomy Reports First Quarter 2015 Financial Results and Provides Corporate Update

SAN DIEGO, May 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
07. Mai 2015 07:00 ET | Quelle: Otonomy, Inc.

Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes

SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
06. Mai 2015 07:30 ET | Quelle: Otonomy, Inc.

Otonomy to Present at Two Upcoming Investor Conferences

SAN DIEGO, May 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
30. April 2015 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Appoints George Morrow to Board of Directors

SAN DIEGO, April 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
28. April 2015 07:00 ET | Quelle: Otonomy, Inc.

Otonomy Announces FDA Acceptance of AuriPro(TM) New Drug Application

SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
27. April 2015 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Presents AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference

SAN DIEGO, April 27, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
21. April 2015 07:30 ET | Quelle: Otonomy, Inc.

Otonomy to Present AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference

SAN DIEGO, April 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
20. April 2015 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients

SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
01. April 2015 07:00 ET | Quelle: Otonomy, Inc.

Otonomy Appoints Dean Hakanson, M.D., as Chief Medical Officer

SAN DIEGO, April 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
26. März 2015 07:30 ET | Quelle: Otonomy, Inc.

Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Label Expansion Indication

SAN DIEGO, March 26, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...

Vorherige Seite

Nächste Seite